Cholinesterase inhibition for Alzheimer disease: A meta-analysis of the tacrine trials

JAMA

Volumn 280, Issue 20, 1998, Pages 1777-1782

  Qizilbash, Nawab ^a,g,h   Whitehead, Anne ^b   Higgins, Julian ^c   Wilcock, Gordon ^d,i   Schneider, Lon ^e   Farlow, Martin ^f,i  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d FRENCHAY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f INDIANA UNIVERSITY   (United States)

^g PFIZER INC   (United States)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ Parke Davis Pharmaceuticals

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; TACRINE;

ALZHEIMER DISEASE; BEHAVIOR; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; COGNITION; DOSE RESPONSE; DRUG EFFECT; FUNCTIONAL ASSESSMENT; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0032567128     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.20.1777     Document Type: Review

References (34)

1. Qizilbash N, Lopez Arrieta J, Lewington S. The efficacy of tacrine in Alzheimer's disease. In: Beppu H, van Dongen M, Huppert F, Kaye J, Qizilbash N, Schneider L, eds. Dementia Module of the Cochrane Database of Systematic Reviews 1997 [book on CD-ROM and online]. Oxford, England: Update Software Cochrane Library; 1997:3.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;4:939-944.
3. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
4. Guy W. Clinical Global Impressions: ECDEU Assessment Manual for Psychopharmacology. Rev ed. Rockville, Md: Dept of Health, Education and Welfare; 1976:218-222. Publication ADM 76-338.
5. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology. 1994;44:2315-2321.
6. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
7. DeJong R, Osterlund OW, Roy GW. Measurement of quality of life changes in patients with Alzheimer's disease. Clin Ther. 1989;11:545-554.
8. Whitehead A, Whitehead JA. General parametric approach to the meta-analysis of randomised clinical trials. Stat Med. 1991;10:1665-1677.
9. Whitehead A, Jones NMB. A meta-analysis of clinical trials involving different classifications of response into ordered categories. Stat Med. 1994; 13:2503-2515.
10. Davies B, Andrews D, Stargatt R, et al. Tetrahydroaminoacridine in Alzheimer's disease. Int J Geriatr Psychiatry. 1990;5:317-321.
11. Fitten LJ, Ferryman KM, Gross PL, et al. Treatment of Alzheimer's disease with short-and long-term oral THA and lecithin: a double-blind study. Am J Psychiatry. 1990;147:239-242.
12. Minthon L, Gustafson L, Dalfelt G, et al. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia. 1993;4:32-42.
13. Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. BMJ. 1990;300:495-499.
14. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. N Engl J Med. 1990;322:1272-1276.
15. Ahlin A, Nyback H, Junthe T, et al. THA in Alzheimer's dementia: clinical, biochemical and pharmacokinetic findings. In: Iqbal K, McLachlan DCR, Winblad B, Wisniewski HM, eds. Alzheimer's Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies. New York, NY: John Wiley & Sons Inc; 1991:522-532.
16. Molloy DW, Guyatt GH, Wilson DB, et al. Effects of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease. CMAJ. 1991;144:29-34.
17. Davis KL, Thai LJ, Gamzu E, et al. Tacrine in patients with Alzheimer's disease: a double-blind, placebo-controlled multicenter study. N Engl J Med. 1992;327:1253-1259.
18. Farlow M, Gracon SI, Hershey LA, et al. A 12-week, double-blind, placebo-controlled, parallel-group study of tacrine in patients with probable Alzheimer's disease. JAMA. 1992;268:2523-2529.
19. Wilcock GK, Surmon DJ, Scott M, Boyle M, Mulligan K, Neubauer KA. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. Age Ageing. 1993;22:316-324.
20. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, for the Tacrine Study Group. Controlled trials of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994; 271:985-991.
21. Maltby N, Broe GA, Creasy H, Jorm AF, Christensen H, Brooks WS. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial. BMJ. 1994;308:879-883.
22. Wood PC, Castleden CM. A double-blind, placebo-controlled, multicentre study of tacrine for Alzheimer's disease. Int J Geriatr Psychiatry. 1994;9: 649-654.
23. Forette F, Hoover T, Gracon S, et al. A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer's disease. Eur J Neurol. 1995;2:1-10.
24. Foster NL, Peterson RC, Gracon SI, Lewis K, for the Tacrine 970-6 Study Group. An enriched population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. Dementia. 1996;7:260-266.
25. Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc. 1997;45:923-928.
26. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.
27. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in Alzheimer's disease patients. Neurology. In press.
28. Ferris SH, Mackel JA, Mohs R, et al. A multicenter evaluation of new treatment efficacy instruments for AD clinical trials. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S1-S12.
29. Nordberg A, Lilja A, Lundquist H, et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging. 1992;13:747-758.
30. Farlow MR, Brashear A, Hui S, Schneider L, Unverzagt F, and the Tacrine Study Group. The effects of tacrine in patients with mild versus moderate stage Alzheimer's disease. In: Iqbal K, Mortimer JA, Winblad B, Wisniewski HM, eds. Research Advances in Alzheimer's Disease and Related Disorders. New York, NY: John Wiley & Sons Inc; 1995:283-292.
31. Eagger S, Levy R. Serum levels of tacrine in relation to clinical response in Alzheimer's disease. Int J Geriatr Psychiatry. 1992;7:115-119.
32. Davis KL, Powchik P. Tacrine. Lancet. 1995; 345:625-630.
33. Knopman D, Schneider L, Davis K, et al, and the Tacrine Study Group. Long-term tacrine treatment: effects of nursing home placement and mortality. Neurology. 1996;47:166-177.
34. Smith F. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients. J Biopharm Stat. 1996;6:59-67.